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Abstract
CONNECTING THE DOTS: INVESTIGATING THE EFFECTS OF TRANS-SYNAPTIC TAU
TRANSMISSION IN THE HIPPOCAMPUS
Michael Adeniran Bamisile, Master of Science
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Anatomy and Neurobiology at Virginia Commonwealth University.
Virginia Commonwealth University, 2019
Rory McQuiston, PhD., Professor, Department of Anatomy and Neurobiology

Tauopathy, which results from the oligomerization of misfolded tau protein in
neurons, is a feature present in a number of neurodegenerative diseases and a hallmark of
Alzheimer’s Disease (AD). Tau is an important phosphoprotein that regulates the assembly of
microtubules, but tauopathy can occur when tau becomes hyperphosphorylated. Phosphorylation
prevents tau from binding to tubulin, which results in cytosolic accumulation of tau and eventual
oligomerization. This abnormal accumulation of tau leads to the spreading of
hyperphosphorylated tau to downstream synaptically connected neurons through an unknown
mechanism. In AD, the hippocampus is one of the first brain structures to be affected by
tauopathy in humans. According to previous research, tauopathy occurs primarily between
principal cells in the hippocampus. The involvement of local inhibitory interneurons in tauopathy
and their potential role in AD is more controversial. Previous research suggests that tau
pathogenesis primarily affects principal cells; however, given the importance, diversity, and
function of interneurons in the hippocampus, it is important to gain a better understanding of the
interneuron subtypes that may be impacted by the spread of trans-synaptic tau into the
hippocampus. Understanding the involvement of interneurons in trans-synaptic tau transmission
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is important to understanding neurodegeneration in AD and other neurodegenerative disorders.
To investigate this, both male and female genetically-modified mice underwent surgery to
examine the trans-synaptic spread of pathogenic tau (EGFP-Tau P301L) from the entorhinal
cortex to hippocampal neurons. Histology and imaging analysis of brain sections were performed
to examine the hippocampal cells impacted by trans-synaptic spread of tau. Results show that
pathogenic tau can trans-synaptically spread from presynaptic neurons in the entorhinal cortex
into downstream hippocampal interneurons and also that hippocampal interneurons are capable
of trans-synaptically spreading tau. Future studies examining the specific subtypes of
hippocampal interneurons vulnerable to trans-synaptic spread of tau will be important for a better
understanding of disease progression, which could lead to uncovering new therapeutic targets for
neurodegenerative diseases, like AD, which are associated with tauopathy.
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Background
Alzheimer’s Disease
In just half a century, the life expectancy of the world has increased significantly.
According to the data collected by The World Bank, an individual’s average life expectancy rose
from 53 years old in 1960 to 72 in 2016 (Life expectancy, 2019). Globally, people are getting
older; however, with increased longevity comes an increase in the probability of developing agerelated diseases such as Alzheimer’s disease (AD). In the United States alone, 5.3 million
individuals have been diagnosed with AD with 5.1 million of these individuals being 65 years
old or older. Thus, this is a disease predominantly affecting older individuals, and in a few years
its prevalence is expected to significantly rise (Alzheimer’s Association, 2015).
AD is characterized as a neurodegenerative disorder in which the progression of the
disease results in memory loss and cognitive impairment (Khyade, Khyade, & Jagtap, 2016;
Wilson et al., 2012). Dementia has been defined by Folstein and McHugh as “the clinical
syndrome of mental life characterized by substantial global decline in cognitive function that is
not attributable to alteration in consciousness” (Breitner, 2006). The degree of dementia
increases as an individual goes through four stages: pre-dementia, early (mild), moderate, and
advanced (severe) (Khyade, Khyade, & Jagtap, 2016). Pre-dementia and the early stage of AD
are characterized by impaired learning and memory; however, individuals are still capable of
living independently in these stages (Storandt & Hill, 1989). In these early stages, verbal
memory is typically the first aspect of memory that is affected (Linn et al., 1995). In moderate
and severe stages of AD, individuals are unable to live independently and memory/cognition are
severely impaired compared to the predementia and early stages of AD (Khyade et al., 2016).
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Furthermore, in these later stages, individuals have a three year life expectancy (Wimo, Winblad,
Stoffler, Wirth, & Mobius, 2003).
As the sixth leading cause of death in the United States (“2015 Alzheimer’s disease facts
and figures,” 2015), the impact of AD has motivated researchers to investigate the pathological
basis of the disease. There are three popular hypothesis to explain the cause of AD: the genetic or
amyloid cascade hypothesis, the cholinergic hypothesis, and the tau hypothesis (Khyade et al.,
2016). The genetic or amyloid hypothesis posits that a number of genetic mutations occur in the
amyloid precursor protein (APP) or in catalytic enzymes involved in processing APP (presenilin
1 and 2) (Price, Tanzi, Borchelt, & Sisodia, 1998). It is believed that in the amyloid cascade
hypothesis, the amyloid precursor protein is cleaved in the endosomal-lysosomal pathway to
form amyloid beta, which is then released into the extracellular space resulting in amyloid beta
plaque formation (O’Brien & Wong, 2011) Accumulation of amyloid beta plaques can
eventually result in neurofibrillary tangles evident in later stages of AD (Hardy & Higgins, 1992;
Maccioni, Farías, Morales, & Navarrete, 2010). However, the role of amyloid beta in the disease
state remains unclear because research has shown that amyloid beta plaques can exist in a normal
cognitive brain (Morris, Clark, & Vissel, 2014). In contrast, no confirmed genetic mutations have
been causally correlated to the far more prevalent late-onset form of AD. However, previous
research suggest that expression of the APOE4 isoform of apolipoprotein E has a weak
correlation to an individual acquiring late-onset sporadic AD; and, in contrast, the APOE2
isoform appears to have protective effects against AD (Strittmatter & Roses, 1996). The
cholinergic hypothesis posits that cholinergic neurons, which are important for learning and
memory, are some of the first neuronal subtypes to be impacted at the onset of AD (P. T Francis,
Palmer, Snape, & Wilcock, 1999; Terry, 2003). This hypothesis provides a useful
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pharmaceutical strategy (combatting the loss of cholinergic neurons) that has worked well for
early stages of AD; however, its efficacy diminishes as AD progresses to later stages (Bartus,
2000). The most popular hypothesis amongst the three, the tau hypothesis, suggests that tau
hyperphosphorylation and aggregation is the key factor for AD (Maccioni et al., 2010). Tau
hyperphosphorylation, spread, and aggregation is also known as tauopathy, and many researchers
are in agreement that this is likely an important underlying cause of AD (Fernández, Rojo,
Kuljis, & Maccioni, 2008; Kosik, Joachim, & Selkoe, 1986; Maccioni, Rojo, Fernández, &
Kuljis, 2009; Rojo et al., 2008).

Tauopathy
Tauopathy is a feature present in a number of neurodegenerative diseases associated with
dementia and cognitive decline. It is a hallmark of AD (Rojo et al., 2008), but several other
diseases also display tau-dependent neurofibrillary tangles such as Argyrophilic grain disease
(Tolnay & Clavaguera, 2004), supranuclear palsy, corticobasal degeneration, Pick’s Disease,
frontotemporal dementia, (Wattez & Delacourte, 1999; Spillantini, Van Swieten, & Goedert,
2000) and Parkinson’s Disease (Lei et al., 2010), all of which are associated with increased
dementia and cognitive decline. The involvement of tau in many neurogenerative diseases should
come as no surprise given the important function tau has in the central nervous system.
Tau is an important phosphoprotein that regulates the assembly of microtubules
(Weingarten et al., 1975). In human, the coding sequence for the microtubule associated protein
tau (MAPT) gene is located on chromosome 17 and is alternatively spliced to produce 6 isoforms
(Goedert, Wischik, Crowther, Walker, & Klug, 1988). Studies indicate that tau, although also
located in the peripheral nervous system, is predominantly located in axons of neurons of the
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central nervous system (Shin et al., 1991), supporting the observation that tau is particularly
important in microtubule organization of axons (Harada et al., 1994). Tau is able to regulate
microtubules by being phosphorylated by a protein kinase, PKN (Taniguchi et al., 2001);
however, it can also be phosphorylated and dephosphorylated by a range of proteins (Billingsley
& Kincaid, 1997).
Tauopathy occurs at least in part because tau becomes hyperphosphorylated.
Phosphorylation of specific residues prevents tau from binding to tubulin, which results in
cytosolic accumulation of tau and eventual oligomerization (Lindwall & Cole, 1984). This
abnormal accumulation of tau leads to the trans-synaptic spread of hyperphosphorylated tau by
an unknown mechanism (Rojo et al., 2008). This abnormal phosphorylation is a serious concern
not only because of aggregation and trans-synaptic spread, but because destabilized microtubules
in neurons (axons predominantly) results in a compromised axonal transport system, which can
ultimately lead to cell death (Kosik et al., 1986). This cell death helped early scientists identify
which brain regions are first affected by tauopathy as cell death appears to occur in a serial
fashion.

The Entorhinal Cortex, Hippocampus, and Tauopathy
In AD, the first brain structure in humans to be affected by tauopathy is the entorhinal
cortex (Braak & Del Tredici, 2012; Gómez-Isla et al., 1996; Khan et al., 2014; Moreno et al.,
2007; Whitwell et al., 2007), more specifically the transentorhinal cortex (Braak & Braak, 1995).
The entorhinal cortex is located in the medial temporal lobe and functions as the “gate-keeper”
between the neocortex and the hippocampus. The entorhinal cortex is usually separated into two
regions: the medial entorhinal cortex and the lateral entorhinal cortex. Both lie next to each other
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and encode different modalities. The medial entorhinal cortex is primarily involved in spatial
memory (Tsao et al., 2018). This is supported by studies that have shown a correlation between
spatial memory diminishing and the volume of the medial entorhinal cortex decreasing (Fox et
al., 1996; Frisoni et al., 1999). The lateral entorhinal cortex is primarily involved in novel objectcontext recognition (Wilson et al., 2013). Layer II and layer III in both the medial and lateral
entorhinal cortex each project to different region and areas in the hippocampus. Layer II of the
medial entorhinal cortex projects to the middle third portion of the molecular layer in the DG
region of the hippocampus and to the deep portion of the stratum lacunosum-moleculare layer in
the CA3 region of the hippocampus. Layer II of the lateral entorhinal cortex projects to the outer
third portion of the molecular layer in the DG region of the hippocampus and the most
superficial portion of the stratum lacunosum in the CA3 region of the hippocampus. Layer III of
the medial entorhinal cortex projects to the CA1 stratum lacunosum adjacent to CA3 region of
the hippocampus. Layer III of the lateral entorhinal cortex projects to CA1 stratum lacunosum
adjacent to the subiculum region of the hippocampus (Canto & Witter, 2012a, 2012b). See
Figure 1 and Figure 2 for connections from the entorhinal cortex.
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Figure 1: Entorhinal Cortex and Hippocampal connections.
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Figure 2: Skutella, T., & Nitsch, R. (2001). New molecules for hippocampal development.
Trends in neurosciences, 24(2), 107-113.
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The hippocampus is the next brain structure to be affected by tauopathy (Fox et al., 1996;
Frisoni et al., 1999). The hippocampus is located in the medial temporal lobe and has been
shown to be primarily involved in learning and memory (Erickson et al., 2011; L. R. Squire,
1986; Larry R. Squire, 1992; Winocur, Wojtowicz, Sekeres, Snyder, & Wang, 2006). Typically,
the hippocampus is divided into four regions: dentate gyrus, CA3 region, CA1 region and
subiculum. See Figure 3 for an image of the hippocampus in rodents.

Figure 3: Torrealba, F., & Valdés, J. L. (2008). The parietal association cortex of the rat.
Biological research, 41(4), 369-377.

According to previous research, the neurons affected by pathogenic tau and transsynaptic spread in the entorhinal cortex and hippocampus are thought to be principal
glutamatergic neurons (Steward & Scoville, 1976; Varga, Lee, & Soltesz, 2010). This finding is
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further supported by research showing that tau trans-synaptically spreads between the principal
cells of each brain structure (Paul T. Francis, 2003; Palop & Mucke, 2010). These findings
suggest that principal cells are exclusively involved in tauopathy; however, concerns arise with
this reasoning because principal cells are not the only cell types residing in the hippocampus and
because there is evidence that interneurons may be involved in tauopathy (Koliatsos et al., 2006;
Loreth et al., 2012; Levenga et al., 2013).

Interneurons and Tauopathy
In addition to principal cells, inhibitory interneurons are another group of cells found in
the hippocampus. Inhibitory interneurons are crucial to the gating of inputs to the hippocampus,
the integration of excitatory inputs within the dendritic trees of principal cells, and the generation
of behaviorally relevant rhythms observed in principal cells of the hippocampus (Freund &
Buzsáki, 1998). Dysfunction in interneurons has also been linked to disrupt cognitive function
as well as play a role in the generation of seizures (Buzsáki, 2002; Chauviere et al., 2009). The
scientific community continues to investigate hippocampal interneurons and the expanding list of
their subpopulations, but we remain in the midst of discovering more inhibitory interneuron
subpopulations that vary in morphology, function, and connectivity. Given the wide range of
roles and functions of interneurons in the hippocampus, investigating how interneurons are
involved in tauopathy could be essential for understanding mechanisms contributing to cognitive
dysfunction in neurodegenerative diseases like AD.
The relationship between interneurons and tauopathy and their potential role in AD
remains contentious. Previous research suggests that interneurons are not actively involved in
trans-synaptic tau transmission (Paul T. Francis, 2003; Verret et al., 2012). Others suggest that
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interneurons have no role in AD (Fu et al., 2019). However, given the diversity and function of
interneuron subtypes, their importance in regulating hippocampal network function, and studies
that suggest that certain interneuron subtypes may be impacted by pathogenic tau, further
investigation into their role in tauopathy and AD is warranted.

Theory
This study aims to identify and classify interneurons and their subtypes impacted by the
trans-synaptic spread of tau. If interneurons are affected, determining what interneuron subtypes
are affected, which hippocampal subregions are being affected, and comparing the relative
number of interneurons to principal neurons being affected is essential to understanding
tauopathy. By providing these answers to our gap in knowledge regarding trans-synaptic spread
of tau in the hippocampus may provide important information necessary for discovering new
therapeutic targets for neurodegenerative disease like AD.

Materials and Methods
Animals
Both adult male and female genetically-modified mice were used to examine the transsynaptic spread of pathogenic tau (EGFP-Tau P301L) from the entorhinal cortex to hippocampal
neurons. To determine the hippocampal cell types vulnerable to the spread of EGFP-Tau P301L
we used the following Cre-recombinase driver mouse lines: Viptm1(cre)Zjh /J (JAX Stock No.
010908), B6;129P2-Pvalbtm1(cre)Arbr /J (JAX Stock No. 008069), Slc32a1 tm2(cre)Lowl/J (JAX
Stock No. 016962), Cr-IRES-Cre (JAX Stock No. 010774), and C57BL/6-Tg(PvalbtdTomato)15Gfng/J (Jax Stock No. 027395) (See Table 1 for purpose of each animal ). The Cre-
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driver lines were crossed to a Cre-dependent tdTomato reporter line Ai14 (B6.CgGT(ROSA)26Sortm14(CAG-tdTomato)Hze/J) (JAX Stock No. 007914 ) to identify VGAT
positive GABAergic interneurons (cells were classified as principal cells based off of
morphology and whether it was VGAT- tdTomato negative). These animals were then crossed
with animals that underwent surgery to selectively infect MEC or ECIII cells using a flex virus
(an AAV1-hSYN1-DIO-GFPtauP301L-WPRE injected in to selectively express pathogenic tau
in Cre-containing principal cells of layer III of the medial entorhinal cortex) that is under the
control of the human synapsin promotor or tTA virus (an AAV1-TRE-GFPtauP301L-WPRE to
selectively express pathogenic tau in tTA-containing principal cells of layer II of the medial
entorhinal cortex) that is under the control of the tetracycline response element. The specifics of
the rationale are explained later in this section. All animals were housed in an animal care
facility approved by the American Association for the Accreditation of Laboratory Animal Care.
Animal experimental procedures followed a protocol approved by the Institutional Animal Care
and Use Committee of Virginia Commonwealth University (AD20205). This protocol adheres to
the ethical guidelines described in the Guide for the Care and Use of Laboratory Safety Animals
(8th edition). All efforts were made to minimize animal discomfort and to reduce the number of
animals used.
Table 1

List of all animal strains and the purpose of each animal used in this experiment.
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Surgery
All instruments were sterilized and an aseptic field was created before surgery. All
animals were initially anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (2.5--5
mg/kg) via intraperitoneal (IP) injection. Atropine was administered to control secretions (0.04
mg/kg) via subcutaneous injection (SC). After animals were placed on the robot stereotaxic
(Neurostar, Tubingen, Germany), the site of incision was wiped with Betadine (Purdue Products
L.P. Stanford, CT 06901-3431) alternated with 70% ethanol three times. During the procedure,
anesthesia was maintained with O2 supplemented with 1.0% isoflurane. An incision was made
along the skull, the skin was pulled back, and a very small hole was drilled over the area of
interest (the entorhinal cortex or the hippocampus). An aluminosilicate glass pipette containing
an adeno-associated virus (AAV) that expressed eGFP-Tau P301L under the control of the
tetracylcine response element (AAV1-TRE-eGFPtau) or the human synapsin promoter (AAV1hSYN1-DIO-GFPtauP301L) was injected into the medial entorhinal cortex (MEC) using a
Hamilton syringe (Hamilton 87930, Franklin, MA) at a rate of 100 nl/min using a motorized
nanoinjector (Neurostar). As a reminder, the animals injected were either a B6.Cg-Tg(Klk8tTA)SMmay/MullMmmh (Stock # 031779-MU) strain (Mutant Mouse Resourse and Research
Center), which is a NOP-tTA animal that allows for specific tTA expression in the layer II
medial entorhinal cortex, or an ECIII (a gift from S. Tonegwa, MIT), which is a pOXR1-Cre
animal that expresses Cre in MEC layer III of the entorhinal cortex. These mice strains were
chosen based off successful previous experiments in our lab and other labs investigating transynaptic tau transmission in the hippocampus. After surgery was complete, animals were
monitored daily for dehydration, lethargy, weight loss and signs of inflammation for minimum of
3 days.
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Tissue Processing for Immunohistochemistry
At specific time points following viral injection (3 -6 months), each animal was deeply
anesthetized with a combination of 200 mg/kg ketamine, 20 mg/kg xylazine IP for tissue
recovery and immunofluorescence processing. These post injection time points were chosen
because this is the earliest time point that we observed trans-synaptic spreading of tau. Once
animals no longer responded to toe pinch, animals were transcardially perfused with ice cold
carbogen-bubbled artificial cerebrospinal fluid (aCSF which contains 125 mM of NaCl, 3.0 mM
of KCl, 1.2 mM of CaCl, 1.2 mM of MgSO4.7H2O, 1.25 mM of NaH2PO4.H2O, 25 mM of
NaHCO3, and 25 mM of glucose) followed by 4% paraformaldehyde (PFA) in phosphate
buffered saline (PBS, Boston BioProducts, Cat # BM-155, pH 7.4 +/- 2). The aCSF was perfused
at 6 mL/min and the 4% PFA was perfused at 2 mL/min using a Peri-Star Pro Pump (Sarasota,
Florida), brains were stored in PFA at 4 degrees for at least 48 hours.
Microscopy was performed at the VCU- Department of Anatomy & Neurobiology
Microscopy Facility, supported in part, with funding from the NIH-NCI Cancer Center Support
Grant P30 CA0116059. Brains were washed in PBS (Quality Biological, Cat. # 119-069-101,
Gaithersburg, Maryland). Brains were then transferred to 30% sterile-filtered sucrose for a few
days until brains saturated, indicated by falling to the bottom of the scintillation vial. Brains were
blocked using a mouse brain matrix and then the blocked brains were embedded in Tissue Tek
O.C.T (Electron Microscopy Sciences, Cat # 62550-01) using a Tissue-Tek Cryomold (Sakura,
Torrance, California). Brains were then hardened using wet ice for 15 minutes followed by dry
ice until O.C.T. was opaque. Once another member of the laboratory had completed the
preceding steps, I performed the following procedures. The tissue was then sectioned using
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ThermoScientific cryostat (Waltham, Massachusetts) at a slice thickness of 20 microns. Cut
brain sections were placed in PBS using a small bristle artist paint brush.
After brain sections were collected, wide field fluorescence microscopy was used to
determine which brain sections had the brightest trans-synaptic eGFP-Tau P301L expression.
Once identified, 15 brain sections encompassing the brightest expression of GFP within the
hippocampus were taken in serial order. Antibodies directed toward cell type specific markers
were used to identify which cell types contained trans-synaptic eGFP-Tau P301L. Primary and
secondary antibodies (See Table #2) were then added per normal protocol using free-floating
brain sections in appropriate blocking buffer. All antibody incubations other than washes were
done at 4 degrees. All washes were done in PBS. Brain sections were mounted on Fisherbrand
colorfrost slides (ThermoScientific, Waltham, Massachusetts) using ProLong Gold antifade
(Invitrogen, Carlsbad, California).

Table 2

Primary and Secondary Antibody List used for this experiment

Quantitative and Qualitative Analysis
All brain sections were stored overnight at room temperature after mounting. Each brain
sections was then examined with the BX53 Upright Microscope (Olympus). During each
examination, the following cell counts were collected by visualization with the OLYMPUS
cellSens dimension software (Olympus): the total number of cells containing trans-synaptic
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pathogenic tau in all sections that successfully underwent antibody incubation, the relative
number of principal cells and inhibitory interneurons located in the dentate gyrus, CA3 and CA1
subregions of the hippocampus, in addition to the relative number of interneurons affected in
each layer of each region of the hippocampus. A total number of 6 transgenic mice were used in
this experiment and a total number of 1,131 cells containing trans-synaptic pathogenic tau were
counted. After examination, brain sections were stored in a -20°C freezer. Brain sections that
best represented the semi-quantitative data were imaged with the BX53 Upright Microscope
(Olympus).

Results
For all experiments, we set out to determine the hippocampal neuronal subtypes in the
hippocampus that were vulnerable to the trans-synaptic spread of tau. How this was
accomplished for each group is described below. For all experiments, all interneurons described
are VGAT positive and fluoresced tdTomato. All other cells were classified as principal cells
once morphology was confirmed. (See Table #3 for the Animal Information and the Counts for
the Total Number of Cells Containing Trans-Synaptic Pathogenic Tau in this experiment).
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Table 3

Animal Information and the Counts for the Total Number of Cells Containing Trans-Synaptic Pathogenic
Tau in this Experiment. Table can also be viewed in the appendix section.
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MEC Injections
In this group, we found that inhibitory interneurons accumulated trans-synaptic spread of
pathogenic tau (Fig. 4 and Fig. 6). In fact, accumulation of trans-synaptic spread of tau was more
prevalent in inhibitory interneurons than principal cells, which is contrary to previous research
concerning the involvement of interneurons in trans-synaptic spreading of tau.
We first examined trans-synaptic spread from Layer II MEC neurons into downstream
hippocampal neurons. We did this by injecting an AAV that expresses GFPtau under the control
of a TRE promoter in MEC-tTA driver mice. The MEC-tTA mouse line primarily expresses tTA
in MEC LII projection neurons; however, a smaller cohort of neurons also express tTA in MEC
LIII. All neurons that received trans-synaptic pathogenic tau by transfecting LII MEC neurons
were taken into account when determining the following proportions.
The proportions that follow are out of the total number of cells that contain trans-synaptic
pathogenic tau in the DG, CA3, and CA1 region of the hippocampus. Cells were classified as
GABAergic (interneuron) or non-GABAergic (principal cells) based on the expression of
tdTomato in GABAergic neurons (VGAT-Cre x ai14 tdTomato reporter). When examining the
DG region, 26% of interneurons contained tau, as opposed to 1% of principal cells (Fig. 5A).
When examining the CA3 region, 8% of interneurons contained tau, as opposed to 1% of
principal cells that contained tau (Fig. 5A). When examining the CA1 region, 6% of interneurons
contained tau, as opposed to 58% of principal cells that contained tau (Fig. 5A).
We next examined the proportions of all the neurons that received trans-synaptic GFPtau
in the DG, CA3, and CA1 subregions of the hippocampus. Cells were classified as GABAergic
(interneuron) or non-GABAergic (principal cells) based on the expression of tdTomato in
GABAergic neurons (VGAT-Cre x ai14 tdTomato reporter). The proportions that follow are
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from the total number of cells that contained trans-synaptic pathogenic tau in the DG, CA3, and
CA1 region of the hippocampus respectively. Of all neurons in the DG region that transsynaptically expressed GFPtau, 13% were interneurons located in the molecular layer, 27% were
interneurons and 2% were principal cells located in the granule cell layer, 54% were interneurons
and 4% principal cells (presumptive mossy cells) located in the dentate hilus (Fig. 5B).
Surprisingly, 94% neurons that contained trans-synaptic pathogenic tau in the DG region were
interneurons, which is in contrast to current hypotheses.
Of all neurons in the CA3 region that trans-synaptically expressed GFPtau, 3% were
interneurons and 5% were principal cells located in the stratum oriens, 29% were interneurons
and 3% were principal cells located in the stratum pyramidale, 24% were interneurons and 3%
were principal cells located in the stratum radiatum, and 31% were interneurons and 3% were
principal cells located in the stratum lacunosum-moleculare (Fig. 5C). Surprisingly, 87% of
neurons that contained trans-synaptic pathogenic tau in the CA3 region were interneurons, which
is in contrast to the current hypotheses.
Of all neurons in the CA1 region that trans-synaptically expressed GFPtau, 2% were
interneurons and 82% were principal cells located in the stratum oriens, 3% were interneurons
and 7% were principal cells located in the stratum pyramidale, 2% were interneurons and 11%
were principal cells located in the stratum radiatum, and 2% were interneurons and 0% were
principal cells located in the stratum laconosum (Fig. 5D).
Because eGFPTau-P301L was found to trans-synaptically spread into a significant
number of GABAergic interneurons, we next attempted to determine whether specific subtypes
of interneurons were more vulnerable to eGFPTau-P301L infection. Calretinin, a calciumbinding protein, is expressed in a small distinct subset of GABAergic interneurons that
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exclusively innervate other interneurons but not principal cells. Modification of calretinin
interneuron function by pathogenic tau could therefore have profound impact on the activity of
the entire population of hippocampal interneurons. Thus, we used immunofluorescence to
determine whether calretinin interneurons were susceptible to the trans-synaptic spread of
eGFPTau-P301L. We detected no spread of eGFPTau-P301L into calretinin neurons in the
molecular or granule cell layer. However, in the hilus of DG, 5% of eGFPTau-P301L expressing
neurons also stained positive for calretinin (Fig. 7). In CA3, all eGFPTau-P301L positive
neurons were negative for calretinin in the stratum oriens and the stratum radiatum. However,
7% of neurons in the stratum pyramidale and 7% in the stratum lacunosum-moleculare were
positive for calretinin interneurons containing trans-synaptic pathogenic tau (Fig. 7).
Interestingly, eGFPTau-P301L did not appear to trans-synaptically spread into CA3 principal
cells in these studies. In CA1, of all the eGFPTau-P301L expressing neurons only 1% of stained
positive for calretinin in the stratum oriens and stratum pyramidale and an additional 6% stained
positive for calretinin in the stratum radiatum. None of the eGFPTau-P301L positive neurons in
the stratum lacunosum-moleculare were also positive for calretinin (Fig. 7). Therefore, although
calretinin neurons only make up a very small percentage of neurons that received the transsynaptic spread of tau, calretinin neurons appear to be involved in trans-synaptic spreading of
tau.
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Figure 4: Medial Entorhinal Cortex Layer II Injection- Targets DG & CA3
A: Tau containing cells are labeled. Arrows point to GFP-tau containing cells that overlap
with VGAT interneurons.
B: VGAT interneurons are labeled. Arrows point to GFP-tau containing cells that overlap
with VGAT interneurons.
C: Arrows point to GFP-tau containing cells that overlap with VGAT interneurons.
D: Picture of the mouse hippocampus. Arrow points to hippocampal region of interest for
this experiment.
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Figure 5: Percentage of Tau Containing Cells after Layer II MEC Injection
A, B, C, & D: Proportions of tau containing cells in each region and sub region of the
hippocampus (P = principal cell; I = interneuron; SM = stratum molecular layer; SG = stratum
granule cell layer; Hilus; SO = stratum oriens; SP = stratum pyramidale; SR = stratum radiatum;
and SLM = stratum laconosum).
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Figure 6: Medial Entorhinal Cortex Layer II Injection- Targets DG & CA3
A: Tau containing cells are labeled. Arrow points to a GFP-tau containing cell.
B: VGAT interneurons fluorescing tdTomato are labeled. Arrow points to a VGAT
interneuron.
C: Calretinin interneurons are labeled. Arrow points to a calretinin interneuron.
D: Calretinin interneurons are a small subset of VGAT interneurons. Arrow points to a VGAT
positive and calretinin positive interneuron.
E: Tau containing cells are labeled. Arrow points to GFP-tau containing cells that overlap with
calretinin interneuron.
F: Picture of the mouse hippocampus. Arrow points to hippocampal region of interest for this
experiment.
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Figure 7: Percentage of Tau Containing Calretinin Positive Cells after Layer II MEC Injection
Proportions of tau containing cells in each region and sub region of the hippocampus (SM = stratum
molecular layer; SG = stratum granule cell layer; Hilus; SO = stratum oriens; SP = stratum pyramidale;
SR = stratum radiatum; and SLM = stratum laconosum).
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ECIII Injections
In this group, we found that inhibitory interneurons accumulated trans-synaptic spread of
pathogenic tau (Fig. 8). In fact, based on proportions, accumulation of trans-synaptic spread of
tau was more prevalent in inhibitory interneurons than principal cells, which is contrary to
previous research concerning the involvement of interneurons in trans-synaptic spreading of tau.
We next examined the trans-synaptic spread of eGFPTau-P301L into postsynaptic
hippocampal neurons following the virally-mediated transfection of LIII neurons of the MEC.
Expression of eGFPTau-P301L depended on Cre-mediated recombination, which was largely
restricted to layer III principal cells in the MEC. Layer III MEC neurons project exclusively to
the CA1 region of the hippocampus. Therefore, we expected to observe trans-synaptic spread of
eGFPTau-P301L into CA1 neurons but not those of the DG or CA3.
The proportions that follow are out of the total number of cells containing trans-synaptic
pathogenic tau in the CA1 region of the hippocampus. As expected, we observed no expression
of eGFPTau-P301L in postsynaptic neurons in the DG or CA3 following eGFPTau-P301L
transfection of LIII MEC projection neurons. When examining the CA1 region, 32% of
interneurons contained trans-synaptic pathogenic tau, as opposed to 68% of principal cells that
contained trans-synaptic pathogenic tau (Fig. 9A). This observation is important as interneurons
as a whole make up less than 20% of the neurons in hippocampal CA1. This suggests that
subsets of hippocampal CA1 inhibitory interneurons may be particular vulnerable to the transsynaptic spread of eGFPTau-P301L.
We next examined the spread of eGFPTau-P301L into neurons of the different layers of
CA1. Of all the interneurons expressing eGFPTau-P301L in CA1, 5 % were found in stratum
oriens, 24% in stratum pyramidale, 3% in stratum radiatum, and none in stratum lacunosum-
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moleculare. For “principal” non-GABAergic neurons, 16% were found in stratum oriens, 48% in
stratum pyramidale, 3% in stratum radiatum, and 1% in stratum lacunosum-moleculare (Fig. 9B).
Because inhibitory interneuron subtypes are found to be preferentially found in different layers,
these findings may guide future studies toward identifying interneuron subtypes that are
particularly vulnerable to the trans-synaptic spread of eGFPTau-P301L.
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Figure 8: Medial Entorhinal Cortex Layer III Injection- Targets CA1
A: Tau containing cells are labeled. Arrows point to GFP-tau containing cells that overlap
with VGAT interneurons.
B: VGAT interneurons are labeled. Arrows point to GFP-tau containing cells that overlap with
VGAT interneurons.
C: Arrows point to GFP-tau containing cells that overlap with VGAT interneurons.
D: Picture of the mouse hippocampus. Arrow points to hippocampal region of interest for this
experiment.
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Figure 9: Percentage of Tau Containing Cells after Layer III MEC Injection
A & B: Proportions of tau containing cells in the CA1 region of the hippocampus (P = principal
cell; I = interneuron; SM = stratum molecular layer; SG = stratum granule cell layer; Hilus; SO =
stratum oriens; SP = stratum pyramidale; SR = stratum radiatum; and SLM = stratum
laconosum).
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vCA1 Injections
In this group, we found that principal cells accumulated trans-synaptic spread of
pathogenic tau (Fig. 10). This suggest that inhibitory interneurons are actively involved in transsynaptic spread of tau, which is contrary to previous research concerning the involvement of
interneurons in trans-synaptic spreading of tau.
Because trans-synaptic tau spreads into a significant proportion of interneurons in
hippocampal CA1, we asked whether CA1 interneurons can trans-synaptically spread tau to CA1
pyramidal cells. To do this we expressed eGFPTau-P301L in GABAergic neurons in
hippocampal CA1 and assessed if eGFPTau-P301L was then passed to postsynaptic CA1
pyramidal neurons. Please refer to Figure 10 and Figure 11 for these findings.
Although we targeted hippocampal CA1 for our AAV eGFPTau-P301L injections, our
injections permitted diffusion of virus into CA3 and DG resulting in expression of eGFPTauP301L in all 3 regions of the hippocampus. When examining the hippocampus as a whole, 11%
of eGFPTau-P301L was found in DG interneurons, 2% in DG principal cells (presumptive
mossy cells), 11% in CA3 interneurons, 10% in CA3 principal cells, 36% in CA1 interneurons,
and 30% CA1 principal cells (Fig. 11 A). Therefore, CA1 interneurons were capable of
transmitting eGFPTau-P301L to postsynaptic CA1 principal cells. However, perhaps more
interesting was the observation that interneurons in DG and CA3 could also trans-synaptically
spread eGFPTau-P301L into principal neurons of the DG and CA3, respectively. This latter
observation was interesting because local interneurons were capable of passing eGFPTau-P301L
to postsynaptic principal cells in DG and CA3 whereas inputs from the entorhinal cortex
appeared incapable. Therefore, it appears that vulnerability to trans-synaptic spread of eGFPTauP301L is synapse specific and perhaps not cell type specific.
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We next examined the layer specific expression of eGFPTau-P301L in each region of the
hippocampus. In the DG, 11% of eGFPTau-P301L neurons were molecular layer interneurons,
3% were molecular layer principal cells, 30% were granule cell layer interneurons, 5% were
granule cell layer principal neurons, 45% were hilar interneurons and 5% were hilar principal
cells (Fig. 11 B). In CA3, 23% of eGFPTau-P301L neurons were in stratum oriens interneurons,
28% were stratum oriens principal cells, 22% were stratum pyramidale interneurons, 2% were
stratum pyramidale principal cells, 23% were stratum radiatum interneurons, and 3% in stratum
radiatum principal cells (Fig. 11 C). No interneurons or principal cells expressing eGFPTauP301L were observed in the stratum lacunosum-moleculare of CA3. In CA1, 26% of eGFPTauP301L neurons were stratum oriens interneurons, 31% were statum pyramidale principal cells
15% were stratum pyramidale interneurons, 8% were stratum pyramidale principal 8% were
interneurons in stratum radiatum, 4% were principal cells in stratum radiatum, 5% were
interneurons in stratum lacunosum-moleculare and 3% were non GABAergic neurons in stratum
lacunosum-moleculare (Fig. 11 D).
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Figure 10: Ventral CA1 Injection
A: Tau containing cells are labeled. Arrows point to GFP-tau containing cells that do not overlap with
VGAT interneurons.
B: VGAT interneurons are labeled.
C: Arrows point to GFP-tau containing cells that do not overlap with VGAT interneurons.
D: Picture of the mouse hippocampus. Arrow points to hippocampal region of interest for this experiment.
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Figure 11: Percentage of Tau Containing Cells after vCA1 Injection
A, B, C, & D: Proportions of tau containing cells in each region and sub region of the
hippocampus (P = principal cell; I = interneuron; SM = stratum molecular layer; SG = stratum
granule cell layer; Hilus; SO = stratum oriens; SP = stratum pyramidale; SR = stratum radiatum;
and SLM = stratum laconosum).
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Discussion
To examine the trans-synaptic spread of eGFPTau-P301L, we used an adeno associated
virus (AAV) strategy in which eGFP-Tau P301L was expressed under the control of the
tetracylcine response element (AAV1-TRE-eGFPtau) or the human synapsin promoter (AAV1hSYN1-DIO-GFPtauP301L) was injected into either layer II of the medial entorhinal cortex
(MEC group), layer III of the medial entorhinal cortex (ECIII group), or ventral CA1 of the
hippocampus (VGATtd group). This was done to identify and classify interneurons and their
subtypes vulnerable to the trans-synaptic spread of tau. Because interneurons were transsynaptically labelled with eGFPTau-P301L, we determined the relative susceptibility of
interneurons to the trans-synaptic spread of tau of interneurons compared to principal neurons
and we further explored which subpopulations of interneurons contained pathogenic tau based on
their anatomical location and co-expression of calretinin. In this study, vesicular GABAergic
transporter (VGAT) interneurons, which is found in all interneurons in the hippocampus,
expressed tdTomato (Rudy, Fishell, Lee, & Hjerling-Leffler, 2011). So, interneurons were
classified as containing pathogenic tau if cells were positive for both GFP and tdTomato.

MEC Injections
The known projection from layer II of the medial entorhinal cortex is to the DG and CA3
region of the hippocampus. We examined trans-synaptic spread from Layer II MEC neurons into
downstream hippocampal neurons. We did this by injecting an AAV that expresses GFPtau
under the control of a TRE promoter in MEC-tTA driver mice. The MEC-tTA mouse line
expresses tTA in MEC LII projection neurons, so we expected eGFPTau-P301L to progress from
layer II of the medial entorhinal cortex and only infect cells (principal cells and interneurons) in
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the DG and CA3 region of the hippocampus. As expected, the DG and CA3 cells of the
hippocampus were contained pathogenic tau. Based on the proportions, it would appear that
interneurons in these regions are more susceptible to trans-synaptic spread of tau. This is
contrary to previous research suggesting that principal cells are predominantly involved in transsynaptic spread of tau. It was also determined that at least one subpopulation of interneurons,
calretinin interneurons, are susceptible to the trans-synaptic spread of tau. GABAergic
interneurons make up about 10% - 15% of cells in the hippocampus (Pelkey et al., 2017) and
calretinin (CR+) interneurons make up a small proportion (~ 10%) of GABAergic interneurons
(Gulyás, Hájos, & Freund, 1996). Although CR+ interneurons that contain pathogenic tau are
small in numbers, the fact that this small subset of interneurons contains trans-synaptic
pathogenic tau is impressive. This finding is also interesting because calretinin interneurons are
interneuron selective and do not innervate principal cells. So, their effect can be significant
through their influence in inhibitory interneurons through disinhibition. Future studies should
determine the other interneurons subpopulations involved in trans-synaptic tau transmission
because our results suggest that other subpopulations are likely to be involved.
Unexpectedly, CA1 cells contained pathogenic tau as well. CA1 cells in this group were
contained tau because, in these mice, some of the cells in layer III of the medial entorhinal cortex
had tTA in them (which allowed for the expression of tau in this pathway). In an ideal mouse
model (one where there is no genetic variability between individuals), cells in layer III of this
group would not have had tTA in them, and ultimately no cells would contain pathogenic tau in
CA1. Due to limitations of the mouse line, the infection of cells in the CA1 region of the
hippocampus were unavoidable.
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ECIII Injections
The known projection from layer III of the medial entorhinal cortex is to the CA1 region
of the hippocampus. We examined the trans-synaptic spread of eGFPTau-P301L into
postsynaptic hippocampal neurons following the virally-mediated transfection of LIII neurons of
the MEC. Expression of eGFPTau-P301L depended on Cre-mediated recombination, which was
largely restricted to layer III principal cells in the MEC. Layer III MEC neurons project
exclusively to the CA1 region of the hippocampus. Therefore, we expected to observe transsynaptic spread of eGFPTau-P301L into CA1 neurons but not those of the DG or CA3. As
expected, the CA1 cells of the hippocampus contained pathogenic tau. Upon further examination
of the CA1 region, it was evident that interneurons contained pathogenic tau. Principal cells in
CA1 appear to contain pathogenic tau in greater number than interneurons; however, about one
third of cells that contain pathogenic tau in this region are interneurons. Keeping this in mind,
since interneurons make up about 15% of neurons in CA1, this finding suggest that subsets of
interneurons may be more susceptible to spread than CA1 principal cells based on probabilities.
If everything was equal, we would have expected about 15% of tau containing neurons to be
interneurons. Interneurons may be more susceptible to trans-synaptic spread of tau and this is
contrary to previous research suggesting that principal cells are predominantly involved in
tauopathy. No cells in the DG region or the CA3 region of the hippocampus contained transsynaptic pathogenic tau because, as expected, layer III of the medial entorhinal cortex does not
project to these regions.
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vCA1 Injections
Ventral CA1 has many known projections outside the hippocampal system, but this
experiment was done to determine if interneurons can trans-synaptically spread tau to CA1
principal cells. To do this we expressed eGFPTau-P301L in GABAergic neurons in hippocampal
CA1 and assessed whether eGFPTau-P301L was trans-synaptically spread to postsynaptic CA1
pyramidal neurons. The rationale for this experiment was that when virus is injected in ventral
CA1, only interneurons will express GFP- tau because only interneurons have cre-recombinase
in this group of mice. If principal cells in CA1 contained tau, this would suggest that
interneurons are actively participating in the trans-synaptic spreading of tau. We did not know
what to expect, except that only interneurons in vCA1 would be expressing GFP-tau in them.
After a 3-month time point, interneurons and principal cells in CA1 both contained transsynaptic pathogenic tau. Additionally, interneurons and principal cells in DG and CA3 also
contained pathogenic tau. The trans-synaptic spread of tau is more than likely due to diffusion
from injection site into the DG and CA3 region of the hippocampus, not due to interneurons
projecting backwards into these regions. Nevertheless, these results from the CA1 region of the
hippocampus suggest that interneurons play an active role in the trans-synaptic spreading of tau.
This is contrary to previous research suggesting that principal cells are exclusively involved in
tauopathy.

Conclusion
Because this was a discovery expedition, this study was more concerned with
determining the trends of trans-synaptic tau transmission associated with hippocampal
interneurons. Contrary to previous research, our results suggest that principal cells are not
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exclusively involved in tauopathy and that interneurons are actively involved in trans- synaptic
tau transmission within the hippocampus. This was determined by observing how tau progresses
from three hippocampal pathways. This study has provided insight into the cell types that are
affected by tauopathy, which is a hallmark of AD and other neurogenerative diseases. This
understanding could lead to the discovery for new therapeutic targets for neurodegenerative
diseases that are associated with tauopathy. More studies concerning the relationship between
tauopathy and interneurons should progress for this discovery.
Limitations, however, did exist in this study. All AAV injections were done manually
through stereotactic surgery and injected into either the entorhinal cortex or the hippocampus to
the best of our abilities. Although mice that received a missed injection were excluded from the
data, minor variability in the injected area of interest will always exist for this type of
methodology. Genetic uniqueness of transgenic animals in this study should also be considered.
Although the transgenic mice from this study were received from professional services and were
properly tested and controlled for, genetic uniqueness for each transgenic animal could have
potentially affected the way trans-synaptic tau activity occurs in each hippocampal system as
well as the cells affected and involved in tauopathy. The number of animals used in this study
should also be considered. About 40 mice were used for this study. Because this was an
exploratory study, some mice were excluded from the data because it was too early of a
timepoint for cells to be affected by tau or too late of a timepoint and tau containing cells were
dead; however, the majority of mice were excluded from this study because they received a
missed injection. The data from this study are from the few successful injections. In the future,
collecting data with more mice will be helpful to determine significance within the study.
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Future studies should also determine the relationship between the role of sex differences
and the prevalence of tau containing interneurons in hippocampal trans-synaptic tau activity.
This study could have potentially given light on this subject, but there were not enough
successful injections to make a worthy suggestion. Future studies should also determine other
interneuron subpopulations affected by trans-synaptic tau transmission. The original plan of this
study was to assess whether more subpopulations, not just calretinin interneurons, contained
trans-synaptic pathogenic tau; however, there was not enough successful injections to examine
other subtypes. Future studies should also determine how interneurons are affected as tau
progresses from other areas of the entorhinal cortex and the hippocampus. This study only
examined the pathways from layer II and layer III of the medial entorhinal cortex as well as
ventral CA1 of the hippocampus. Examining pathways from the lateral entorhinal cortex as well
as other regions of the hippocampus could potentially give insight as to how tau progresses and
the behavior of tau containing interneurons in the hippocampal system.
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